Literature DB >> 6850645

Multivariate analysis of prognostic variables in patients with metastatic testicular cancer.

G J Bosl, N L Geller, C Cirrincione, N J Vogelzang, B J Kennedy, W F Whitmore, D Vugrin, H Scher, J Nisselbaum, R B Golbey.   

Abstract

A majority of patients with metastatic testicular cancer achieve a complete remission as a result of current treatment programs. However, patients who fail to achieve a complete remission have a very poor prognosis, and nearly all die of their disease. A multivariate logistic regression analysis of several clinical variables associated with prognosis was performed using data from 171 patients treated for metastatic testicular cancer at Memorial Hospital between September 1975 and February 1981. A mathematical model was identified which correctly predicted 94% of complete remissions and 83% of all outcomes. The variables achieving statistical significance were the logarithm of the serum values of lactate dehydrogenase (p less than 0.001) and human chorionic gonadotropin (p less than 0.001) and the total number of sites of metastasis (p less than 0.001). The model was tested against 49 patients with metastatic testicular cancer treated at the University of Minnesota Hospitals, and it correctly predicted 86% of complete remissions and 84% of all outcomes. In a highly curable disease such as testicular cancer, mathematical modeling may enable the clinical investigator to anticipate those patients who are least likely to do well. Alternate treatment strategies would be appropriate for such patients.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6850645

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  22 in total

Review 1.  Advances in the treatment of testicular cancer.

Authors:  Hans-Georg Kopp; Markus Kuczyk; Johannes Classen; Arnulf Stenzl; Lothar Kanz; Frank Mayer; Michael Bamberg; Jörg Thomas Hartmann
Journal:  Drugs       Date:  2006       Impact factor: 9.546

2.  Tumour markers in germ cell tumours.

Authors:  G J Rustin
Journal:  Br Med J (Clin Res Ed)       Date:  1986-03-15

3.  Super-high-risk germ-cell tumors: a clinical entity. Report of eleven cases.

Authors:  A Moran-Ribon; J P Droz; J Kattan; B Leclercq; M Ghosn; D Couanet; M Ostronoff; S Culine; B Misset; B Escudier
Journal:  Support Care Cancer       Date:  1994-07       Impact factor: 3.603

Review 4.  The structural relationship of blood group-related oligosaccharides in human carcinoma to biological function: a perspective.

Authors:  V E Dube
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

5.  Curing metastatic testicular cancer.

Authors:  Lawrence H Einhorn
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-19       Impact factor: 11.205

Review 6.  Good-risk-advanced germ cell tumors: historical perspective and current standards of care.

Authors:  Darren R Feldman; Robert J Motzer
Journal:  World J Urol       Date:  2009-06-10       Impact factor: 4.226

7.  Application of the International Germ Cell Consensus Classification to the Nova Scotia population of patients with germ cell tumours.

Authors:  Elana Maydanski Murphy; Jo-Anne Douglas; Kara Thompson; Lori Wood
Journal:  Can Urol Assoc J       Date:  2009-04       Impact factor: 1.862

8.  Comparison of 5 vs 10 micrograms/kg per day of GM-CSF following dose-intensified chemotherapy with cisplatin, etoposide, and ifosfamide in patients with advanced testicular cancer.

Authors:  C Bokemeyer; H J Schmoll; B Metzner; J Beyer; H J Illiger; M Kneba; H Ostermann; B Kynast; U Räth; H Poliwoda
Journal:  Ann Hematol       Date:  1993-08       Impact factor: 3.673

9.  Vascular considerations in postchemotherapy. Retroperitoneal lymph-node dissection: Part II.

Authors:  J P Donohue; J A Thornhill; R S Foster; R Bihrle
Journal:  World J Urol       Date:  1994       Impact factor: 4.226

Review 10.  Hematopoietic growth factors and treatment of testicular cancer: biological interactions, routine use and dose-intensive chemotherapy.

Authors:  C Bokemeyer; M A Kuczyk; H Köhne; H Einsele; B Kynast; H J Schmoll
Journal:  Ann Hematol       Date:  1996-01       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.